Recent studies have found that BRCA1/2, a breast cancer susceptibility gene, is closely related to triple-negative breast cancer (TNBC) and can repair DNA damage through homologous recombination, and its mutation can be used to predict the efficacy of PTX in TNBC chemotherapy [20]. This evidence concerns the gene BRCA1 and triple-negative breast carcinoma.